Genetics in Anti-Platelet Treatment.
Anti-platelet drugs are necessary in treating patients with coronary artery disease, ischemic stroke and peripheral arterial disease. However, despite the use of adequate anti-platelet therapy, some patients will experience a recurrent atherothrombotic vascular event. These patients are characterized as low- or non-responders to therapy. Individual responsiveness to anti-platelet therapy as the use of clopidogrel and/or aspirin varies widely among patients. Such an individual variability is mainly determined by environmental and genetic factors. In this review, we focused on the underlying genetic mechanisms that might influence response to anti-platelet drugs.
Molecular Biology, Department of Basic Medical Science, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Michalakopoulou 176, 11527 Athens, Greece.
Maria
M
Gazouli
D001792:Blood Platelets / Q000187:drug effects; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D058729:Peripheral Arterial Disease / Q000188:drug therapy* / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000235:genetics
D010975:Platelet Aggregation Inhibitors